Johnson & Johnson ( JNJ) reported third-quarter earnings of $3.3 billion, or $1.17 a share, compared with $2.6 billion, or 88 cents a year earlier, as strong sales in the company's medical devices and diagnostics segment boosted results.

Analysts surveyed by Thomson Reuters expected the company to earn $1.11 a share in the quarter.

Sales in the quarter rose $15.9 billion, an increase of 6.4% from a year earlier. Domestic sales rose 0.4%, while international sales rose 13.1%, the company said in a statement Tuesday.

Johnson & Johnson raised its earnings guidance for full-year 2008 to $4.50 to $4.53 a share, excluding the impact of any in-process research and development charges.

"Johnson & Johnson continues to achieve solid earnings results despite the impact that generic products have had on our pharmaceutical business," said William C. Weldon, chairman and CEO. "Of note was the strong sales performance of our consumer segment and the solid sales results in our medical devices and diagnostics segment."

Worldwide consumer sales in the quarter rose 13.1%, while medical devices and diagnostics sales rose 8.8%.

Shares of Johnson & Johnson closed Monday at $62.68.

If you liked this article you might like

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Buy Stocks That Are Right for You: Cramer's 'Mad Money' Recap (Friday 2/16/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

The Decline In Johnson & Johnson Could Be Close to Being Over

The Decline In Johnson & Johnson Could Be Close to Being Over

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report